{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:28:18Z","timestamp":1767144498641,"version":"build-2238731810"},"reference-count":35,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.acvd.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T08:38:22Z","timestamp":1567672702000},"page":"455-458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Proprotein convertase subtilisin\/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications"],"prefix":"10.1016","volume":"112","author":[{"given":"Dennis V.","family":"Cokkinos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Cokkinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genovefa","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2019.06.003_bib0180","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.acvd.2018.10.001","article-title":"The best in coronary artery disease management is yet to come","volume":"111","author":"Angoulvant","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2019.06.003_bib0185","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2019.06.003_bib0190","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2019.06.003_bib0195","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.acvd.2017.07.007","article-title":"Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: determinants and prognostic impact","volume":"111","author":"Bauters","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2019.06.003_bib0200","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.06.003_bib0205","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.06.003_bib0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11883-017-0684-8","article-title":"PCSK9 mutations in familial hypercholesterolemia: from a Groundbreaking discovery to anti-PCSK9 therapies","volume":"19","author":"El Khoury","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.acvd.2019.06.003_bib0215","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/ATVBAHA.110.209007","article-title":"Beyond LDL cholesterol, a new role for PCSK9","volume":"30","author":"Akram","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2019.06.003_bib0220","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating proprotein convertase subtilisin\/kexin Type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors","volume":"133","author":"Leander","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2019.06.003_bib0225","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hlc.2015.10.017","article-title":"Plasma proprotein convertase subtilisin kexin Type 9 as a predictor of carotid atherosclerosis in asymptomatic adults","volume":"25","author":"Chan","year":"2016","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.acvd.2019.06.003_bib0230","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2019.06.003_bib0235","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/ATVBAHA.115.306172","article-title":"Association of proprotein convertase subtilisin\/kexin Type 9 (PCSK9) with cardiovascular risk in primary prevention","volume":"35","author":"Zhu","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2019.06.003_bib0240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2014.07.010","article-title":"PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program","volume":"236","author":"Arsenault","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2019.06.003_bib0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2019.06.003_bib0250","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2019.06.003_bib0255","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.acvd.2019.06.003_bib0260","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1471-2261-14-192","article-title":"Proprotein convertase subtilisin\/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat","volume":"14","author":"Zhang","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.acvd.2019.06.003_bib0265","doi-asserted-by":"crossref","first-page":"e106294","DOI":"10.1371\/journal.pone.0106294","article-title":"Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies","volume":"9","author":"Almontashiri","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.acvd.2019.06.003_bib0270","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/cvr\/cvy128","article-title":"PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2019.06.003_bib0275","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","article-title":"The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF Subanalysis","volume":"70","author":"Bayes-Genis","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.06.003_bib0280","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0300060516648030","article-title":"Proprotein convertase subtilisin\/kexin type 9 levels and aortic valve calcification: a prospective, cross sectional study","volume":"44","author":"Wang","year":"2016","journal-title":"J Int Med Res"},{"key":"10.1016\/j.acvd.2019.06.003_bib0285","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2018.04.064","article-title":"Hemodynamic deterioration of surgically implanted bioprosthetic aortic valves","volume":"72","author":"Salaun","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.06.003_bib0290","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.jacc.2018.09.063","article-title":"PCSK9 involvement in aortic valve calcification","volume":"72","author":"Poggio","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.06.003_bib0295","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2014.02.538","article-title":"Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects","volume":"63","author":"Lambert","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.06.003_bib0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.acvd.2019.06.003_bib0305","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","article-title":"PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling","volume":"69","author":"Kysenius","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.acvd.2019.06.003_bib0310","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2019.06.003_bib0315","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.acvd.2019.06.003_bib0320","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-018-0718-x","article-title":"Pleiotropic anti-atherosclerotic Effects of PCSK9 inhibitors from molecular biology to clinical translation","volume":"20","author":"Karagiannis","year":"2018","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.acvd.2019.06.003_bib0325","first-page":"163","article-title":"Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels","volume":"120","author":"Davignon","year":"2009","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.acvd.2019.06.003_bib0330","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1463-1326.2010.01229.x","article-title":"Fenofibrate concomitantly decreases serum proprotein convertase subtilisin\/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients","volume":"12","author":"Chan","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.acvd.2019.06.003_bib0335","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1194\/jlr.M000620","article-title":"Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels","volume":"51","author":"Troutt","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.acvd.2019.06.003_bib0340","doi-asserted-by":"crossref","first-page":"3179201","DOI":"10.1155\/2018\/3179201","article-title":"Cardiovascular outcomes of PCSK9 Inhibitors: with special emphasis on its effect beyond LDL-cholesterol lowering","volume":"2018","author":"Bandyopadhyay","year":"2018","journal-title":"J Lipids"},{"key":"10.1016\/j.acvd.2019.06.003_bib0345","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cvr\/cvy301","article-title":"What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?","volume":"115","author":"Banach","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2019.06.003_bib0350","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvy293","article-title":"Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology","volume":"115","author":"Tunon","year":"2019","journal-title":"Cardiovasc Res"}],"updated-by":[{"DOI":"10.1016\/j.acvd.2019.10.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000}}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213619301160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213619301160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T22:45:58Z","timestamp":1596235558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213619301160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":35,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1875213619301160"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2019.06.003","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proprotein convertase subtilisin\/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}